title: Clonidine in the treatment of mixed bipolar disorder.
abstract: In a mixed bipolar disorder patient, DST-positive, treated with neuroleptics and antidepressants, the addition of clonidine (up to 0.6 mg/day) caused a rapid improvement in his psychopathology, without any significant side effects. The concentrations of the metabolites of noradrenaline, dopamine, and serotonin (MHPG, HVA, and 5-HIAA), the hormone prolactin and the activity of dopamine-beta-hydroxylase estimated in plasma during the clonidine trial are also reported.
authors: Department of Psychiatry, Athens University Medical School, Eginition Hospital, Greece.
authors: V
authors: V
authors: Kontaxakis
authors: M
authors: M
authors: Markianos
authors: M
authors: M
authors: Markidis
authors: C
authors: C
authors: Stefanis
mesh_terms: D000328:Adult; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000201:enzymology / Q000523:psychology; D003000:Clonidine / Q000627:therapeutic use*; D003907:Dexamethasone; D004299:Dopamine beta-Hydroxylase / Q000097:blood; D005260:Female; D006719:Homovanillic Acid / Q000097:blood; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000097:blood; D008734:Methoxyhydroxyphenylglycol / Q000097:blood; D011388:Prolactin / Q000097:blood; D011569:Psychiatric Status Rating Scales
chemical_list: D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D003907:Dexamethasone; D011388:Prolactin; D004299:Dopamine beta-Hydroxylase; D003000:Clonidine; D006719:Homovanillic Acid